Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

How to efficiently establish animal models of cholangiocarcinoma: challenges and inspiration.

Medical review (2021)·2026

Same author

Men's Preferences for Exiting Abdominal Aortic Aneurysm Surveillance: A Deliberative Engagement Session Study.

Patient preference and adherence·2026

Same author

Abdominal Aortic Aneurysm Intervention Delays: A National Data Review of the England Abdominal Aortic Aneurysm Screening Programme 2017 - 2023.

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery·2026

Same author

Telehealth Exercise Training in Peripheral Arterial Disease (TEXTPAD) study: A pilot randomised controlled trial in socioeconomically disadvantaged populations.

PloS one·2025

Same author

Antibiotics versus topical antiseptics for chronic suppurative otitis media.

The Cochrane database of systematic reviews·2025

Same author

Topical versus systemic antibiotics for chronic suppurative otitis media.

The Cochrane database of systematic reviews·2025

Search research articles

Related Experiment Video

Updated: May 27, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Antiplatelet agents for intermittent claudication.

Peng F Wong¹, Lee Yee Chong, Dimitris P Mikhailidis

¹Department of Vascular Surgery, Freeman Hospital, Newcastle upon Tyne, UK. pwong23@hotmail.com

The Cochrane Database of Systematic Reviews

|November 11, 2011

Summary

Antiplatelet agents significantly reduce mortality in patients with intermittent claudication (IC). While beneficial for reducing cardiovascular events and mortality, they increase adverse effects like gastrointestinal symptoms.

More Related Videos

Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication

Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication

Published on: December 11, 2013

Related Experiment Videos

Last Updated: May 27, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication

Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication

Published on: December 11, 2013

Area of Science:

Cardiology
Vascular Medicine
Pharmacology

Background:

Peripheral arterial disease (PAD) is a common indicator of systemic atherosclerosis.
Intermittent claudication (IC) symptoms signify heightened risk for cardiovascular events and mortality.

Purpose of the Study:

To evaluate the efficacy of antiplatelet agents in mitigating mortality and cardiovascular events in patients with IC.

Main Methods:

Systematic review and meta-analysis of double-blind randomized controlled trials.
Included trials compared oral antiplatelet agents against placebo or other antiplatelet agents.
Excluded patients with asymptomatic PAD, advanced PAD (Fontaine stage III-IV), or those undergoing intervention.

Main Results:

Antiplatelet agents reduced all-cause mortality (RR 0.76) and cardiovascular mortality (RR 0.54) versus placebo.
No statistically significant reduction in total cardiovascular events was observed (RR 0.80).
Antiplatelets other than aspirin showed a lower risk of all-cause mortality and cardiovascular events compared to aspirin.
Increased risk of adverse events, including gastrointestinal symptoms and therapy cessation, was noted.
Risk of limb deterioration requiring revascularization was significantly reduced (RR 0.65).

Conclusions:

Antiplatelet agents offer benefits in reducing mortality for IC patients.
Increased adverse effects necessitate awareness of both benefits and harms.
Further research is needed on major bleeding risks and comparative effectiveness of aspirin versus thienopyridines.